Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04451863 · ClinicalTrials.gov registry record · Phase 1
Analgesic and Subjective Effects of Terpenes
A Phase 1 study of Pain and Abuse, Drug, sponsored by University of California, Los Angeles.
- Active
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT04451863: Active Phase 1 study of Pain and Abuse, Drug, sponsored by University of California, Los Angeles.
NCT04451863 is a Phase 1 study of Pain and Abuse, Drug that is active but no longer recruiting, run by University of California, Los Angeles. The registered enrollment target is 45 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04451863, a Phase 1 study of Pain and Abuse, Drug, is active but no longer recruiting, sponsored by University of California, Los Angeles.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to assess the analgesic and subjective effects of terpenes administered alone and in combination of THC.
Primary Outcome
Pain threshold and pain tolerance assessed using the Cold Pressor Test
Conditions Studied
Interventions
- DRUG Low THC
- DRUG High THC
- DRUG Low Myrcene
- DRUG High Myrcene
- DRUG Low Beta-Caryophyllene
Study Locations (1)
California
- University of California, Los Angeles - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2021-12-15 |
| Est. Completion | 2026-04-30 |
| Phase | Phase 1 |
What the registry record for NCT04451863 still lists
NCT04451863 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 304-participant average among 374 other Pain trials with a reported enrollment target (85% lower).
The record links to 2 conditions, with Pain appearing as the primary indexed condition, and to 5 interventions - of which Low THC is the first listed.
NCT04451863 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04451863 about?
NCT04451863 is a clinical study titled "Analgesic and Subjective Effects of Terpenes". The purpose of this research is to assess the analgesic and subjective effects of terpenes administered alone and in combination of THC.
What is the current status of trial NCT04451863?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2021-12-15. Estimated completion is 2026-04-30.
What conditions does trial NCT04451863 study?
This clinical trial studies the following conditions: Pain, Abuse, Drug.
What interventions are being tested in trial NCT04451863?
The interventions under investigation include: Low THC (DRUG), High THC (DRUG), Low Myrcene (DRUG), High Myrcene (DRUG), Low Beta-Caryophyllene (DRUG).
Who is sponsoring clinical trial NCT04451863?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04451863 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04451863's enrollment target sits among peer trials
45 272nd of 374 higher than 99 of 374 other Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
THC and CBD: A Controlled Human Study Probing a Harm Reduction Strategy
RECRUITING · Phase 1
-
Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Participants
RECRUITING · Phase 1
-
Ketamine Pharmacokinetics and Pharmacodynamics for Postpartum Depression and Pain After Cesarean Delivery
RECRUITING · Phase 1
-
High Potency Cannabis: Acute and Protracted Effects
RECRUITING · Phase 1
-
Phase 1 Study of SBS-147 in Healthy Adults
RECRUITING · Phase 1
-
Patient Controlled Administration of Liquid Acetaminophen
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI